WFDC2 and cystic fibrosis: Recently, CF patients treated with CFTR potentiator ivacaftor (IVA) and carrying at least one Class III CFTR CF-causing mutation (p.Gly551Asp) had lower plasma HE4 concentrations, which also inversely correlated with the improvement of their spirometry parameters (Nagy et al., 2019).